In this scenario, it is plausible that decreased functionality of MeCP2 early in life, as that seen in RTT patients, will impact the epigenetic programming of the HPA axis thereby affecting their vulnerability to develop anxiety and stress-related disorders later in life, when encountering a stressor. The gene discussed is MECP2; the disease is stress-related disorder.